QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:RARE

Ultragenyx Pharmaceutical News Headlines

$118.63
-6.67 (-5.32 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$116.44
Now: $118.63
$126.15
50-Day Range
$125.30
MA: $145.21
$167.73
52-Week Range
$31.99
Now: $118.63
$179.65
Volume465,991 shs
Average Volume466,050 shs
Market Capitalization$7.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19

Headlines

Ultragenyx Pharmaceutical (NASDAQ RARE) News Headlines Today

Source:
SourceHeadline
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to C- by TheStreetUltragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to C- by TheStreet
marketbeat.com - February 18 at 7:10 AM
First Week of March 19th Options Trading For Ultragenyx Pharmaceutical (RARE)First Week of March 19th Options Trading For Ultragenyx Pharmaceutical (RARE)
nasdaq.com - March 4 at 2:22 PM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 26% Above Their Intrinsic Value EstimateUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 26% Above Their Intrinsic Value Estimate
finance.yahoo.com - March 4 at 9:22 AM
Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) SVP Sells 732 Shares of StockInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) SVP Sells 732 Shares of Stock
americanbankingnews.com - March 3 at 10:44 PM
Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 4,572 Shares of StockInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 4,572 Shares of Stock
americanbankingnews.com - March 3 at 9:56 PM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $4,254,000.00 in StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $4,254,000.00 in Stock
americanbankingnews.com - March 3 at 9:56 PM
Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells 6,198 Shares of StockInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells 6,198 Shares of Stock
americanbankingnews.com - March 3 at 9:56 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE)  Shares Down 10.5% Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 10.5%
americanbankingnews.com - March 3 at 9:12 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at Stifel NicolausUltragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at Stifel Nicolaus
americanbankingnews.com - March 1 at 5:19 PM
Ultragenyx: Multiple Potential Catalysts AheadUltragenyx: Multiple Potential Catalysts Ahead
finance.yahoo.com - February 19 at 1:30 PM
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenUltragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
finance.yahoo.com - February 17 at 8:43 AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $178.00 at SVB LeerinkUltragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $178.00 at SVB Leerink
americanbankingnews.com - February 16 at 9:25 AM
Piper Sandler Comments on Ultragenyx Pharmaceutical Inc.s Q1 2022 Earnings (NASDAQ:RARE)Piper Sandler Comments on Ultragenyx Pharmaceutical Inc.'s Q1 2022 Earnings (NASDAQ:RARE)
americanbankingnews.com - February 15 at 3:48 AM
Zacks: Analysts Anticipate Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Will Post Earnings of -$1.02 Per ShareZacks: Analysts Anticipate Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Will Post Earnings of -$1.02 Per Share
americanbankingnews.com - February 14 at 12:14 AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 7.7%Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 7.7%
americanbankingnews.com - February 12 at 8:18 PM
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat EstimatesUltragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates
finance.yahoo.com - February 12 at 1:22 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $170.00Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $170.00
americanbankingnews.com - February 12 at 11:37 AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to "Neutral" at JPMorgan Chase & Co.Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to "Neutral" at JPMorgan Chase & Co.
americanbankingnews.com - February 12 at 10:08 AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Increased to $186.00 by Analysts at BarclaysUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Increased to $186.00 by Analysts at Barclays
americanbankingnews.com - February 12 at 9:34 AM
Ultragenyx Pharmaceutical Inc. 2020 Q4 - Results - Earnings Call PresentationUltragenyx Pharmaceutical Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 12 at 7:26 AM
Ultragenyx Pharmaceutical Inc (RARE) Q4 2020 Earnings Call TranscriptUltragenyx Pharmaceutical Inc (RARE) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 12 at 12:39 AM
Ultragenyx Pharmaceutical, Inc. to Host Earnings CallUltragenyx Pharmaceutical, Inc. to Host Earnings Call
finance.yahoo.com - February 11 at 7:38 PM
Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdateUltragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - February 11 at 7:38 PM
Recap: Ultragenyx Pharmaceutical Q4 EarningsRecap: Ultragenyx Pharmaceutical Q4 Earnings
finance.yahoo.com - February 11 at 7:38 PM
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue EstimatesUltragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - February 11 at 7:38 PM
Can Ultragenyx Stock Rise Continue?Can Ultragenyx Stock Rise Continue?
forbes.com - February 11 at 9:35 AM
IWO, RARE, DECK, NTRA: Large Outflows Detected at ETFIWO, RARE, DECK, NTRA: Large Outflows Detected at ETF
nasdaq.com - February 5 at 10:48 PM
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
finance.yahoo.com - February 4 at 9:28 AM
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson DiseaseUltragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
finance.yahoo.com - January 21 at 1:21 PM
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & GuidanceUltragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
finance.yahoo.com - January 12 at 12:17 PM
Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx TerritoriesUltragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories
finance.yahoo.com - January 11 at 10:12 AM
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy StudiesUltragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
finance.yahoo.com - January 8 at 3:39 PM
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States | Business WireArcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States | Business Wire
businesswire.com - January 6 at 8:36 PM
Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare ConferenceUltragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
finance.yahoo.com - January 5 at 1:40 PM
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Can Easily Afford To Drive Business GrowthWe Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Can Easily Afford To Drive Business Growth
finance.yahoo.com - December 28 at 5:25 PM
Ultragenyx: Upside But Not Without RiskUltragenyx: Upside But Not Without Risk
seekingalpha.com - December 21 at 10:31 PM
Is RARE A Good Stock To Buy Now?Is RARE A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 5:39 PM
Ultragenyx Pharma Earns Membership In 95-Plus Composite Rating ClubUltragenyx Pharma Earns Membership In 95-Plus Composite Rating Club
finance.yahoo.com - December 14 at 5:49 PM
Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseUltragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease
finance.yahoo.com - December 9 at 5:40 PM
Ultragenyx to Present at Upcoming Healthcare ConferencesUltragenyx to Present at Upcoming Healthcare Conferences
finance.yahoo.com - November 24 at 9:07 AM
Rare disease drug maker Ultragenyx plans to hire 100-150 at new gene therapy facility near BostonRare disease drug maker Ultragenyx plans to hire 100-150 at new gene therapy facility near Boston
bizjournals.com - November 9 at 7:25 PM
Ultragenyx to build gene therapy manufacturing facilityUltragenyx to build gene therapy manufacturing facility
seekingalpha.com - November 9 at 2:25 PM
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare DiseasesUltragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
finance.yahoo.com - November 9 at 9:23 AM
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesUltragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
marketwatch.com - November 4 at 7:23 PM
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesUltragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 2 at 11:36 AM
Ultragenyx Shows Rare StrengthUltragenyx Shows Rare Strength
finance.yahoo.com - October 30 at 10:24 PM
Earnings Update: Heres Why Analysts Just Lifted Their Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target To US$102Earnings Update: Here's Why Analysts Just Lifted Their Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target To US$102
finance.yahoo.com - October 29 at 11:14 AM
Solid Biosciences (SLDB) to PostQ3 Earnings: Whats in Store?Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?
finance.yahoo.com - October 28 at 5:41 PM
Ultragenyx Announces Proposed Public Offering of Common StockUltragenyx Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 28 at 12:40 PM
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat EstimatesUltragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
finance.yahoo.com - October 28 at 12:40 PM
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - October 28 at 7:24 AM
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.